Home Latest News
Respironics® Launches the REMstar® Plus M Series Sleep System

MURRYSVILLE, Pa., April 25, 2006 – Respironics, Inc. (NASDAQ/NMS Symbol: RESP) recently released its REMstar Plus M Series with C-Flex™, the first model in its M Series line of sleep systems. The REMstar M Series is the only complete line of sleep therapy systems that provides proven patient comfort and ease of use in a sleek, modern design. The products are designed for the treatment of adults who have obstructive sleep apnea.

To help make therapy more comfortable, the REMstar Plus M Series features C-Flex technology. C-Flex tracks the patient’s breathing and lowers the amount of pressure delivered during exhalation. With three settings, patients have the ability to select the level of pressure relief that’s right for them, without altering the benefits of prescribed therapy. C-Flex helps to make exhaling against the CPAP pressure easier, providing a more comfortable treatment and ultimately increasing the likelihood of compliance.

In a recent study involving both CPAP and C-Flex users, remarkably, after three months, patients using C-Flex technology used their therapy an average of one-hour and 42-minutes longer per night than patients on traditional CPAP. Additionally, patients using C-Flex had a significantly greater satisfaction with treatment comfort and interface comfort, and greater overall satisfaction with therapy at six months.

With its small size, three easy-to-use primary control buttons and more lifestyle-oriented design, the REMstar M Series is targeted at improving the patient’s acceptance to therapy. Other comfort features, such as ramp and integrated humidification, are also incorporated into the design. The optional ramp feature reduces the air pressure when a patient is trying to fall asleep and then gradually increases (or ramps) the pressure until the device reaches the patient’s prescription setting. For patients using humidification, a less obtrusive humidifier chamber adds to the sleek appearance of the platform, and is easier to remove and fill.

The REMstar M Series has also been designed with an improved monitoring system to make data management more efficient. Reports are easily accessible to read and share among physicians/clinicians, homecare providers and patients. Some models are also equipped with an Encore® Pro SmartCard® accessory module to record information for the homecare provider, and the self-management feature allows the proactive user to monitor and verify the effectiveness of therapy.

Says Jeff Maglin, Global Product Manager, Sleep Therapy, “Nothing gives us greater satisfaction than creating a product that’s packed with proven features that help improve acceptance, comfort and results for its users. These advances are what make Respironics the leader in sleep therapy.”

† Top Of Page


About Respironics

Respironics’ Sleep and Home Respiratory Group is recognized worldwide for its continuous stream of medical innovations and advancements in the management of sleep disorders, chronic respiratory problems, and neonatal and pediatric care. The Group integrates state-of-the-art technology in diagnostics, therapy and monitoring with strategic problems to help health care providers, sleep centers and pediatric units care for patients efficiently and cost-effectively.

Respironics is a leading developer, manufacturer and distributor of innovative products and programs that serve the global sleep and respiratory markets. Focusing on emerging market needs, the Company is committed to providing valued solutions to help improve outcomes for patients, clinicians and health care providers. Respironics markets its products in 131 countries and employs over 4,500 associates worldwide. Further information can be found on the Company’s Web site: global.respironics.com.

This document contains forward-looking statements, including statements relating to, among other things, developments in the healthcare industry; the success of the Company's marketing, sales, and promotion programs; future sales and acceptance of the Company's products and programs; the timing and success of new product introductions; new product development; anticipated cost savings; FDA and other regulatory requirements and enforcement actions; future results from acquisitions; acquisition integration; growth rates in foreign markets; regulations and other factors affecting operations and sales outside the United States (including potential future effects of the change in sovereignty of Hong Kong); foreign currency fluctuations; customer consolidation and concentration; increasing price competition and other competitive factors in the sale of products; interest rate fluctuations; expiration of intellectual property rights; intellectual property and related litigation; other litigation; future levels of earnings and revenues; and third party reimbursement, all of which are subject to change. Actual results may differ materially from those described in any forward-looking statements. Additional information on potential factors that could affect the Company's financial results are included in the reports filed with the SEC, including the reports on Form 10-K, 10-Q and 8-K.

© 2006 Respironics, Inc. and its affiliates

† Top Of Page